An imbalance in gene activity in two types of immune cells explains why lung fibrosis after a severe COVID-19 infection doesn ...

A recent study revealed that early-life exposure to tobacco significantly elevates the risk of developing idiopathic ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company focused on developing innovative therapies for ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

STOCKHOLM, SE / ACCESS Newswire / January 29, 2025 / Vicore Pharma Holding (STO:VICO)Stockholm, January 29, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Discover the connection between genetic risk factors for idiopathic pulmonary fibrosis and the development of post-COVID-19 ...

Columnist Sam Kirton says that at his age, and as someone with pulmonary fibrosis, he's had much experience dealing with grief.

Increase in incidences of cancer worldwide and favorable reimbursement policies provided by manufacturers & insurance providers drive the growth of the market ...

Her parent has Idiopathic pulmonary fibrosis - an incurable condition which causes scarring to the lungs and reduces her ability to breathe, meaning she relies on supplemental oxy ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who ...